Last €0.54 EUR
Change Today +0.03 / 5.85%
Volume 0.0
C5V On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 2:20 AM 12/23/14 All times are local (Market data is delayed by at least 15 minutes).

cardica inc (C5V) Snapshot

Open
€0.53
Previous Close
€0.51
Day High
€0.54
Day Low
€0.53
52 Week High
01/9/14 - €1.02
52 Week Low
11/21/14 - €0.41
Market Cap
48.3M
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
89.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CARDICA INC (C5V)

Related News

No related news articles were found.

cardica inc (C5V) Related Businessweek News

No Related Businessweek News Found

cardica inc (C5V) Details

Cardica, Inc. designs, manufactures, and markets automated anastomotic systems for use by cardiac surgeons to perform coronary bypass surgery in the United States and internationally. It provides C-Port Distal Anastomosis systems, including C-Port xA Anastomosis systems to perform an end-to-side distal anastomosis by attaching the end of a bypass graft to a coronary artery downstream of an occlusion or narrowing; C-Port Flex A Anastomosis systems to enable automated anastomoses to be performed as part of coronary artery bypass grafting procedures; and PAS-Port Proximal Anastomosis systems to perform an end-to-side proximal anastomosis between a saphenous vein and the aorta. It also offers endoscopic microcutter products comprising MicroCutter XCHANGE 30, MicroCutter FLEXCHANGE 30, and MicroCutter XCHANGE 45 cartridge based microcutter devices to facilitate endoscopic procedures requiring cutting and stapling; and MicroCutter XPRESS 30 and MicroCutter XPRESS 45 multi-fire endolinear microcutter devices for the bariatric and thoracic surgery markets. In addition, the company licenses its intellectual property in the robotics field in diagnostic or therapeutic medical procedures. The company markets its Port Distal Anastomosis systems through its direct sales force, as well as through independent manufacturers’ representatives and distributors. The company was formerly known as Vascular Innovations, Inc. and changed its name to Cardica, Inc. in November 2001. Cardica, Inc. was founded in 1997 and is headquartered in Redwood City, California.

75 Employees
Last Reported Date: 11/12/14
Founded in 1997

cardica inc (C5V) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $455.8K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $280.0K
Vice President of Operations
Total Annual Compensation: $254.3K
Vice President of Research & Development
Total Annual Compensation: $282.3K
Vice President of Sales and Marketing
Total Annual Compensation: $114.6K
Compensation as of Fiscal Year 2014.

cardica inc (C5V) Key Developments

Cardica Inc. Announces Board Changes

Cardica Inc. announced that three members of the board of directors Kevin Larkin, Chairman of the Board; Richard Powers; and Jeffrey Purvin have agreed to transition off the board by not standing for reelection at the upcoming 2014 annual meeting, thereby ensuring that Broadfin's three director nominees will be elected to the board; With Mr. Larkin's transition off the board, The company's board has appointed Gary Petersmeyer, a newly appointed independent member of the board, as its chairman, effective immediately.

Cardica Inc., Annual General Meeting, Dec 11, 2014

Cardica Inc., Annual General Meeting, Dec 11, 2014. Agenda: To re-elect all directors.

Cardica Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended September 30, 2014

Cardica Inc. reported unaudited consolidated earnings results for the first quarter ended September 30, 2014. For the quarter, total net revenue was approximately $1,068,000, compared to $805,000 for the fiscal 2014 first quarter. Loss from operations was $4,959,000 against $3,621,000 a year ago. Net loss was $5,065,000 or $0.06 per basic and diluted share compared with $3,739,000 or $0.07 per basic and diluted share a year ago. Total product sales were approximately $1.1 million, compared to $0.7 million for the fiscal 2014 first quarter. Revenue from the U.S. increased substantially to approximately $274,000 with revenue from Europe impacted by the summer quarter and relatively flat compared to last quarter.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
C5V:GR €0.54 EUR +0.03

C5V Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cytori Therapeutics Inc $0.48 USD -0.0141
Pluristem Therapeutics Inc $2.46 USD 0.00
Stereotaxis Inc $1.36 USD -0.03
Uroplasty Inc $2.30 USD 0.00
Vision Sciences Inc/DE $0.76 USD -0.07
View Industry Companies
 

Industry Analysis

C5V

Industry Average

Valuation C5V Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 15.8x
Price/Book 3.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CARDICA INC, please visit www.cardica.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.